Publication

A UNICANCER phase III trial of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis (PC) PRODIGE 7

ANNÉE

2018

AUTEURS

Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, Juzyna B, de Forges H, Paineau J, Glehen O, UNICANCER-GI Group and BIG Renape Group

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.18_suppl.LBA3503

Activité Physique Adaptée et Cancer du Pancréas Etude APACaP

ANNÉE

2018

AUTEURS

Neuzillet C

CONGRÈS/REVUE

AFSOS

PRODIGE 52 -UCGI 29-CCTG/CO.27 (IROCAS) A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (A UNICANCER GI-PRODIGE trial)

ANNÉE

2018

AUTEURS

Bennouna J, Andre T, Miglianico L, Campion L, Mineur L, Heng Lam Y, Hire St, Artru P, Bouche O, Borde F, Aleba A, Rajpar LS, Rebischung C, Touchefeu Y, Kavan P, Gill S, Asmis T, JouffroyZeller C, Emile JF, Taieb J

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS3622

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)

ANNÉE

2018

AUTEURS

Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2018.01.119

Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK)

ANNÉE

2018

AUTEURS

Michel P, Boige V, Andre T, Aparicio T, Bachet JB, Dahan L, Guimbaud R, Lepage C, Manfredi S, Tougeron D, Taieb J, Selves J, Le Malicot K, Di Fiore F, Maillard E

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2017.12.023

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

ANNÉE

2018

AUTEURS

Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, Cunha AS

CONGRÈS/REVUE

BMC Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1186/s12885-018-4663-4

Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01

ANNÉE

2018

AUTEURS

Goere D, Pignon JP, Gelli M, Elias D, Benhaim L, Deschamps F, Caramella C, Boige V, Ducreux M, de Baere T, Malka D

CONGRÈS/REVUE

BMC Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1186/s12885-018-4697-7

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study

ANNÉE

2018

AUTEURS

Walter T, Malka D, Hentic O, Lombard-Bohas C, Le Malicot K, Smith D, Ferru A, Assenat E, Cadiot G, Lievre A, Kurtz JE, Dahan L, Dubreuil O, Hautefeuille V, Lepere C, Gangloff A, Elhajbi F, Coriat R, Roquin G, Bouarioua N, Granger V, Scoazec JY, Lepage C

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2017.11.020

Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study

ANNÉE

2018

AUTEURS

Phelip JM, Edeline J, Blanc JF, Barbier E, Michel P, Bourgeois V, Neuzillet C, Malka D, Manfredi S, Desrame J

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2018.11.018

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX)

ANNÉE

2018

AUTEURS

Dahan L, Phelip JM, Le Malicot K, Williet N, Desrame J, Volet J, Petorin C, Malka D, Rebischung C, Aparicio T, Lécaille C, Rinaldi Y, Turpin A, Bignon A, Bachet JB, Seitz JF, Lepage C, Francois E

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4000